$77.91
1.14 (-1.44%)
Last updated: May 31, 2026 07:46
Fundamentals Overview
Arrowhead Pharmaceuticals, Inc. is near the high of its 52-week range with premium valuation, trading relatively flat today.
Valuation premium
Risk (Beta)
1.29 — higher vol
BullzEye Analysis
Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.
Composite Signal
Supporting (Buy):
Sentiment improving (1 upgrade) · 3M vs S&P 500: +17.3% · 3M vs Healthcare sector: +31.7%
Pressures (Sell):
Analyst grade: D+
Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.
Key Stats
About
Ratings & Grades at a Glance
Overall rating: D+. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 15, Equal Weight: 3, Market Perform: 1, Neutral: 3, Outperform: 4, Overweight: 4.
Valuation & Ratios
Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.
DCF vs price: DCF estimate is $-99.80; current price is $77.91. That’s a -228.1% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.
| Metric | Value |
|---|---|
| Valuation | |
| P/E (TTM) | N/A |
| PEG (TTM) | N/A |
| P/B (TTM) | 18.07 |
| P/S (TTM) | 17.64 |
| Liquidity & enterprise | |
| Current Ratio (TTM) | 6.23 |
| Quick Ratio (TTM) | 6.23 |
| Cash Ratio (TTM) | 0.64 |
| Profitability | |
| ROE (TTM) | N/A |
| ROA (TTM) | N/A |
| Revenue growth (YoY) | N/A |
| Net margin (TTM) | -48.38% |
| Gross margin (TTM) | 100% |
| Operating margin (TTM) | -35.67% |
| Debt to equity (TTM) | N/A |
Latest News
News loads when you open this tab.
Price Target, Ratings & Grades
Analyst price targets, consensus, rating snapshot, and institutional grades for ARWR.
Analyst Sentiment at a Glance
Stock Grades (Institutions)
| Institution | Action | Previous Grade | New Grade | Date |
|---|---|---|---|---|
| Bernstein | maintain | Market Perform | Market Perform | 2026-05-13 |
| RBC Capital | maintain | Outperform | Outperform | 2026-05-08 |
| Morgan Stanley | upgrade | Equal Weight | Overweight | 2026-04-21 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-03-25 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-02-10 |
| B. Riley Securities | maintain | Buy | Buy | 2026-01-22 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2026-01-21 |
| Piper Sandler | maintain | Overweight | Overweight | 2026-01-13 |
| Goldman Sachs | maintain | Neutral | Neutral | 2026-01-07 |
| Morgan Stanley | maintain | Equal Weight | Equal Weight | 2026-01-07 |
| Chardan Capital | maintain | Buy | Buy | 2026-01-07 |
| Piper Sandler | maintain | Overweight | Overweight | 2025-12-17 |
| RBC Capital | maintain | Outperform | Outperform | 2025-12-11 |
| B of A Securities | maintain | Buy | Buy | 2025-12-09 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-12-02 |
| B of A Securities | maintain | Buy | Buy | 2025-12-01 |
| Chardan Capital | maintain | Buy | Buy | 2025-12-01 |
| Morgan Stanley | maintain | Equal Weight | Equal Weight | 2025-11-26 |
| Goldman Sachs | maintain | Neutral | Neutral | 2025-11-20 |
| Chardan Capital | maintain | Buy | Buy | 2025-11-19 |
| Piper Sandler | maintain | Overweight | Overweight | 2025-11-19 |
| RBC Capital | maintain | Outperform | Outperform | 2025-11-19 |
| Morgan Stanley | maintain | Equal Weight | Equal Weight | 2025-11-12 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-10-08 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-09-02 |
| Chardan Capital | maintain | Buy | Buy | 2025-08-11 |
| RBC Capital | maintain | Outperform | Outperform | 2025-08-08 |
| HC Wainwright & Co. | maintain | Buy | Buy | 2025-05-20 |
| Citigroup | maintain | Neutral | Neutral | 2025-05-13 |
| Chardan Capital | maintain | Buy | Buy | 2025-05-13 |